NR1D1 Validated Chimera RNAi
- Known as:
- NR1D1 Validated Chimera RNAi
- Catalog number:
- H00009572-R01V
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- NR1D1 Validated Chimera RNAi
Related genes to: NR1D1 Validated Chimera RNAi
- Gene:
- NR1D1 NIH gene
- Name:
- nuclear receptor subfamily 1 group D member 1
- Previous symbol:
- THRAL
- Synonyms:
- ear-1, hRev, Rev-ErbAalpha, THRA1, REVERBA, REVERBalpha
- Chromosome:
- 17q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-04-16
- Date modifiied:
- 2018-02-14
Related products to: NR1D1 Validated Chimera RNAi
20kDa Growth Hormone, 27-202 aa, Human, E.coli (Bioactivity Validated)20kDa Growth Hormone, 27-202 aa, Human, E.coli (Bioactivity Validated)20kDa Growth Hormone, 27-202 aa, Human, E.coli (Bioactivity Validated)5(6)_FAM [5_(and_6)_Carboxyfluorescein] *Validated for labeling peptides and oligos*5(6)_FAM [5_(and_6)_Carboxyfluorescein] *Validated for labeling peptides and oligos*5(6)_FAM [5_(and_6)_Carboxyfluorescein] *Validated for labeling peptides and oligos*5(6)_FAM [5_(and_6)_Carboxyfluorescein] *Validated for labeling peptides and oligos*5(6)_FAM, SE [5_(and_6)_Carboxyfluorescein, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_FAM, SE [5_(and_6)_Carboxyfluorescein, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_FAM, SE [5_(and_6)_Carboxyfluorescein, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_FAM, SE [5_(and_6)_Carboxyfluorescein, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_TAMRA, SE [5_(and_6)_Carboxytetramethylrhodamine, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_TAMRA, SE [5_(and_6)_Carboxytetramethylrhodamine, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_TAMRA, SE [5_(and_6)_Carboxytetramethylrhodamine, succinimidyl ester] *Validated for labeling peptides and oligos*5(6)_TAMRA, SE [5_(and_6)_Carboxytetramethylrhodamine, succinimidyl ester] *Validated for labeling peptides and oligos* Related articles to: NR1D1 Validated Chimera RNAi
- Endometritis, a prevalent inflammatory disease in dairy cattle, causes substantial economic losses to the dairy industry. Conventional therapies mainly rely on antibiotic treatment, but this often leads to bacterial resistance and antibiotic residues in milk. Thus, it is essential to identify novel and effective therapeutic methods for endometritis treatment in dairy cows. The activation of nuclear receptor subfamily 1 group D member 1 (NR1D1), an important circadian clock component, potently attenuates inflammatory responses in various diseases through transcriptional repression of its downstream target genes. In spite of the growing evidence for NR1D1 regulation of inflammatory diseases, its involvement in the curing of bovine endometritis remains largely unidentified. Recently, berberine (BBR), a natural isoquinoline alkaloid, has been identified as a natural NR1D1 agonist. The present study was aimed to investigate the role of NR1D1 in bovine endometritis, and to elucidate the potential therapeutic effect of BBR on endometritis treatment and its underlying mechanisms by targeted activation of NR1D1, using bovine endometrial epithelial cell line (BENDs) and mouse model treated by Escherichia coli lipopolysaccharide (LPS). In comparison with their control groups, NR1D1 expression was elevated in uterine tissues from cows with endometritis and in BENDs treated with 1 μg/mL LPS for 12 h, accompanying by the upregulation of IL-6, IL-1β, IL-8, and CCL5 expression. Activation of NR1D1 by SR9009 (a synthetic NR1D1 agonist) or lentiviral overexpression of NR1D1 markedly reduced the levels of proinflammatory cytokines (IL-6, IL-1β, and CCL5) and critical NF-κB pathway proteins (p-p65 and p-IκB), whereas NR1D1 inhibition or knockout conversely resulted in a pronounced upregulation of proinflammatory cytokines and NF-κB pathway proteins. Subsequently, BBR treatment attenuated LPS-induced inflammatory response in both BENDs and the mouse endometrium; however, this anti-inflammatory effect was abolished in NR1D1-deficient BENDs. In addition, western blotting detected robust circadian rhythmicity of NR1D1 in the uterus of mouse model, and BBR treatment at zeitgeber time (ZT) 8 showed the better therapeutic efficacy on attenuating the mouse endometrial inflammatory response than at ZT20, displaying a time-dependent treatment manner. In conclusion, BBR alleviates LPS-induced inflammatory response by targeted activation of NR1D1 in BENDs, and that the anti-inflammatory efficacy of berberine in a mouse model of endometritis is time-dependent. These findings suggest that NR1D1 is a promising therapeutic target for bovine endometritis, and its natural agonist BBR potentially act as an anti-inflammatory compound for the prevention and treatment of bovine endometritis. - Source: PubMed
Publication date: 2026/05/18
Yang WanghaoWang XuerongXiao BonanLi ChaoGuo YiyingTang KeqiongWang AihuaChao Hsu-WenJin YapingChen Huatao - Heat stress (HS) disturbs hepatic metabolic homeostasis and redox balance, compromising antioxidant capacity and mitochondrial function. Ferroptosis, a lipid peroxidation-associated form of regulated cell death, has been implicated in redox-sensitive metabolic disorders. Whether nutritional timing influences HS-associated ferroptotic responses in the liver remains unclear. This study examined the effects of time-restricted feeding (TRF) on hepatic redox regulation and ferroptosis-related molecular pathways under chronic heat exposure. - Source: PubMed
Publication date: 2026/05/12
Zhu YanliYuan LongZhu CuipengKim In HoTyasi Thobela LouisHu PingWang ShengchenAhmed Abdelkareem ALiu Hao-YuCai Demin - Chronic stress partially leads to depression through the gut-brain axis, yet the underlying multi-level mechanisms remain unclear. This study aims to delineate the pathway from chronic restraint stress (CRS) to depressive-like behaviors, focusing on interactions among gut microbiota, their metabolites, and host transcriptional responses in the colon and hippocampus. - Source: PubMed
Publication date: 2026/04/29
Wang XuliLiu RuisiLin YudongZhou Mingmei - Many transcription factors may be involved in the pathogenesis of pulmonary fibrosis (PF). One such factor is PPARG. The PPARG agonist, pioglitazone (PG), has demonstrated general lung protective activity in animal models and is considered a promising therapeutic agent for fibrotic intervention. This study aimed to investigate the effect of PG on the expression of connective tissue remodeling genes in the lungs using bleomycin (BLM)-induced lung fibrosis (BIF). - Source: PubMed
Publication date: 2026/05/04
Kabaliei AlinaPalchyk VitalinaIzmailova OlgaShynkevych ViktoriyaShlykova OksanaKaidashev Igor - Liver fibrosis can be accelerated by oxidative stress and inflammatory damage. The effect of liquiritigenin (LQ) on ferroptosis in liver fibrosis is what this research intends to explore. - Source: PubMed
Publication date: 2026/04/19
Guo XinHuang Bao-NianZuo Jing-YuTai YiLiu Xue-KunDu RuiJin Xue-Jun